
Andrew Huntley
Managing Partner, Head of Healthcare
ロンドン, ホーチミン
Andrew Huntley is a Managing Partner of BDA. Having joined the co-founders in 1998, he established and oversaw BDA’s early Asian offices including Singapore, Shanghai and Hong Kong, subsequently co-managed BDA’s New York office from 2002 to 2005, and managed its London office from 2005 to 2018.
He now travels widely in Asia and Europe from his base in Ho Chi Minh City and oversees BDA’s global Healthcare & Life Sciences sector. Mr. Huntley has advised clients on transactions across Asia as well as in Europe and North America, including both blue chip corporate clients such as Arkema, Celestica, Clariant, Edenred, Henkel, Jardine Matheson, Johnson Matthey, Laird Group, Rexel, Sumitomo Chemical, SunGard, ThomsonReuters, Tata Motors and Weir Group as well as financial sponsors such as Actis, Ardian, Bregal Capital, EQT, LDC, Investcorp, Mekong Capital, Nova Capital, Prudential, Segulah, Seera and STIC. Before BDA, Mr. Huntley worked for the Jardine Matheson Group in HK, China, Taiwan and Vietnam. He acted as the Group Representative in Vietnam and had executive responsibility for Group businesses there and in Taiwan. Mr. Huntley was educated at Oxford University (MA Hons, Chinese). He is fluent in Mandarin and conversant in Vietnamese.
Recent transactions

has been acquired by


2023

received investment from


2023

a portfolio company of

has been acquired by

2022

agreed to divest East Syracuse, New York facility to


2022

Debt and equity restructuring
2022

a portfolio company of

has been acquired by

2022

investment from


2021

has been acquired by


2021

a portfolio company of

divested 100% to

2021

a portfolio company of

divested 100% to

2021

a portfolio company of

has been acquired by

2021

raised Series B round from


2021

backed by

has been acquired by

2020

divested Escientia Life Sciences to Deccan Fine Chemicals


2020

divested significant stake in

Kehua Bio-Engineering to Gree Real Estate
2020

majority sale
2019

divested majority stake to


2019

a portfolio company of

has been acquired by

2018

a portfolio company of

has been acquired by

AGIC and Humanwell
2017

OEP Turkey Tech divested its 48.08% equity stake in

to

2017


















